{"id":"peg-rhg-gsf","safety":{"commonSideEffects":[{"rate":null,"effect":"Bone pain"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL405705","moleculeType":"Small molecule","molecularWeight":"1256.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This drug is a long-acting formulation of G-CSF created by conjugating polyethylene glycol (PEG) to recombinant human granulocyte colony-stimulating factor. The pegylation extends the drug's half-life, allowing for less frequent dosing compared to non-pegylated G-CSF. It binds to G-CSF receptors on hematopoietic progenitor cells, promoting their proliferation, differentiation, and mobilization into peripheral blood.","oneSentence":"PEG-rhG-CSF is a pegylated recombinant human granulocyte colony-stimulating factor that stimulates the production and release of neutrophils from bone marrow to increase white blood cell counts.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:26:04.256Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced neutropenia (CIN)"},{"name":"Severe chronic neutropenia"},{"name":"Peripheral blood progenitor cell mobilization"}]},"trialDetails":[{"nctId":"NCT06563869","phase":"PHASE3","title":"Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-02-02","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Polyethylene glycolylated recombinant human granulocyte stimulating factor"],"phase":"phase_3","status":"active","brandName":"PEG-rhG-GSF","genericName":"PEG-rhG-GSF","companyName":"The First Affiliated Hospital with Nanjing Medical University","companyId":"the-first-affiliated-hospital-with-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PEG-rhG-CSF is a pegylated recombinant human granulocyte colony-stimulating factor that stimulates the production and release of neutrophils from bone marrow to increase white blood cell counts. Used for Chemotherapy-induced neutropenia (CIN), Severe chronic neutropenia, Peripheral blood progenitor cell mobilization.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}